Results 181 to 190 of about 5,335 (288)

Epidemiological Survey and Genomic Insights Into Ostreid Herpesvirus 1 Transmission in the Blood Clam Anadara broughtonii in China (2019–2025)

Animal Research and One Health, EarlyView.
Seven‐year surveillance reveals a cold‐adapted OsHV‐1 lineage in blood clams, with disease onset at 13°C—3–5°C lower than in oysters—and identifies asymptomatic carriers and facility effluent as key transmission routes. ABSTRACT Ostreid herpesvirus 1 (OsHV‐1) poses a major threat to bivalve aquaculture, but its impact on blood clams (Anadara ...
Xiang Zhang, Bowen Huang, Tao Yu, Jingli Wang, Maole Wei, Huigang Kang, Chongming Wang, Changming Bai   +7 more
wiley   +1 more source

Pathophysiological Mechanisms of Emaciation Syndrome in Plectropomus leopardus: Insights From Histology and Transcriptomics

Animal Research and One Health, EarlyView.
Integrated phenotypic, histological, transcriptomic, and validation analyses reveal that emaciation syndrome in Plectropomus leopardus is associated with intestinal structural damage, hepatic metabolic remodeling, and muscle protein degradation, highlighting coordinated multi‐tissue alterations underlying disease progression.
Zhihao Zhang, Bo Wang, Mengya Wang, Haizhan Tang, Mingjian Liu, Da Zheng, Zhongyi Zhai, Jiahang Li, Jinyang Xie, Chaofan Jin, Jingjie Hu, Zhenmin Bao   +11 more
wiley   +1 more source

Patients 40 Years of Age or Older Have Comparable Return to Sport Rates, Reinjury Rates, and 2‐Year Patient‐Reported Outcomes After Medial or Lateral Meniscus Repair Compared With Patients Younger Than 40 Years of Age

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To compare patient‐reported outcomes, return to sport (RTS), and reinjury rates after meniscus repair in patients over and under the age of 40 years old. Methods Meniscus repair cases performed at a single tertiary care center between December 2010 and August 2021 with a minimum 2‐year follow‐up data were reviewed.
Alexander E. White, Tyler J. Uppstrom, Akshay K. Raghuram, Thun Itthipanichpong, Samarth V. Menta, Robert B. Baldwin, Shu‐Han Wang, Anil S. Ranawat   +7 more
wiley   +1 more source

Gender Equity in Rheumatology Research: Global Analysis of Authors

Arthritis &Rheumatology, EarlyView.
Objective To investigate gender representation of authors in rheumatology research over the last decade. Methods Using metadata from original and review articles published between 2015 and 2024 in SCImago top two quartile (Q1, Q2) rheumatology journals, author gender was classified using two public databases.
Michael Girdwood, Jean W. Liew, Ida K. Haugen, Marcella F. Pazzinatto, Andrea M. Bruder, Nicola Dalbeth, Adam G. Culvenor, Tuhina Neogi   +7 more
wiley   +1 more source

On absence and abundance: biography as method in archival research. [PDF]

Area (Oxf), 2017
Hodder J.
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Chimpanzees are not more aggressive than bonobos but target sexes differently. [PDF]

Sci Adv
Bryon E, Roth TS, Torfs JRR, Eens M, van Leeuwen EJC, Staes N.   +5 more
europepmc   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Alberto Martini, Daniel L. Lovell, Nicolino Ruperto   +52 more
wiley   +1 more source

The Significance of Lived Experience in the Work of Social Reformer and Nursing Pioneer Elizabeth Fry (1780-1845). [PDF]

Int J Ment Health Nurs
Raeburn T, Chang CR, Penny J, Ireland M.
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source